Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV

1867.00

Share Price

1733.00

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 58.76%
Worldwide Healthcare (Ordinary Share) NAV 69.25%
FTSE World 19.16%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 1730.0 -7.4% 1867.00 1832.00
19 May
112% 0.72%

Discrete performance % over

Fund / BenchmarkJun '13
May '14
Jun '14
May '15
Jun '15
May '16
Worldwide Healthcare (Ordinary Share) Price12.7654.24-8.72
Worldwide Healthcare (Ordinary Share) NAV15.2359.25-7.77
FTSE World1.6118.26-0.83

Discrete performance over

Discrete Performance

Top 10 Holdings

ONO Pharmaceutical Co., Ltd. 5.47%
Allergan, Inc. 5.47%
HCA Holdings Inc 5.06%
Bristol-Myers Squibb Company 4.25%
AbbVie Inc 4.15%
Amgen Inc 3.54%
Boston Scientific, Inc. 3.34%
Intuitive Surgical, Inc. 3.24%
Regeneron Pharmaceuticals, Inc. 2.94%
Biogen Idec Inc., 2.73%

Sectors weighting

Pharmaceuticals 98.80%
Net Current Assets 1.20%

Regional weighting

North America Region 68.00%
Europe Developed ex-UK 13.00%
Japan 10.00%
Other Countries 4.00%
Asia exc Japan 3.00%
Cash/Cash Equivalent 2.00%
Fixed Interest 1.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Currency GBX
  • Domicile UK
  • Share Price 1733.00
  • Share Type Ordinary Share
  • TIDM WWH
  • ISIN GB0003385308
  • Shares Issued (M) 47
  • Market Capital (£M) 818.45
  • Gross Assets (£M) 990.87
  • Net Assets (£M) 884.14
  • TER (%) 0.96
  • Historic Dividend Yield (%) 0.72
  • Last AGM 24 Sep 2015
  • Next AGM 24 Sep 2016
  • Last Annual Report Date 16 Jun 2014
  • Next due Report Date 31 Mar 2015
  • Next due Report Type A/R
  • Objective:

  • To invest worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
  • Management Group(s):

  • Close Finsbury Asset Management Ltd
  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Samuel. D Isaly Start: 28 Apr 1995
  • Sven Borho Start: 01 Feb 2013
  • Trevor M. Polischuk Start: 31 Mar 2015
  • Management Contract & Fees:

    OrbiMed, the Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may be terminated by either party giving notice of not less than 12 months. Frostrow, the Administrator, receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to £150m, 0.20% p.a. of the market capitalisation in excess of £ 150m and up to £500m, and 0.125% p.a. of the market capitalisation in excess of £500m, plus a fixed amount equal to £ 57,500 p.a.. Dependent on the level of long-term outperformance of the Company, the Investment Manager and the Administrator are entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment Manager receiving 15% and the Administrator receiving 1.5% respectively.